

Dipak Kotecha, Fesc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3626707/publications.pdf>

Version: 2024-02-01

107
papers

31,698
citations

61984

43
h-index

32842

100
g-index

116
all docs

116
docs citations

116
times ranked

21620
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	2.2	5,689
2	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
3	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
4	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	1.7	3,523
5	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	2.2	2,517
6	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.	2.2	899
7	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
8	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	1.4	754
9	Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet, The, 2014, 384, 2235-2243.	13.7	475
10	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 2018, 39, 26-35.	2.2	426
11	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	1.7	370
12	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 2217-2228.	2.8	292
13	2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Revista Espanola De Cardiologia (English Ed), 2017, 70, 50.	0.6	280
14	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ, The, 2015, 351, h4451.	6.0	247
15	Atrial fibrillation in heart failure: what should we do?. European Heart Journal, 2015, 36, ehv513.	2.2	243
16	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	1.8	220
17	Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. Journal of the American College of Cardiology, 2017, 69, 2885-2896.	2.8	198
18	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. Journal of the American Heart Association, 2017, 6, .	3.7	187

#	ARTICLE	IF	CITATIONS
19	Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. <i>European Heart Journal</i> , 2018, 39, 1481-1495.	2.2	163
20	Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. <i>International Journal of Cardiology</i> , 2016, 203, 660-666.	1.7	161
21	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	1.7	121
22	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2497.	7.4	118
23	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , 2017, 103, 1024-1030.	2.9	104
24	Digoxin: The good and the bad. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 585-595.	4.9	102
25	Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2017, 22, 731-741.	3.9	98
26	A Practical Guide to Assess the Reproducibility of Echocardiographic Measurements. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 1505-1515.	2.8	98
27	European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. <i>Europace</i> , 2018, 20, 225-233.	1.7	97
28	Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. <i>European Heart Journal</i> , 2019, 40, 1268-1276.	2.2	96
29	Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. <i>BMJ, The</i> , 2016, 353, i1855.	6.0	95
30	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	1.7	95
31	2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPED IN COLLABORATION WITH EACTS. <i>Russian Journal of Cardiology</i> , 2017, , 7-86.	1.4	87
32	Echocardiographic Structure and Function in Hypertensive Disorders of Pregnancy. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	2.6	86
33	Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. <i>European Journal of Heart Failure</i> , 2009, 11, 872-880.	7.1	85
34	Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. <i>Europace</i> , 2018, 20, f153-f161.	1.7	80
35	Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. <i>Europace</i> , 2020, 22, 748-760.	1.7	72
36	Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trials. <i>American Heart Journal</i> , 2011, 161, 822-831.e2.	2.7	67

#	ARTICLE	IF	CITATIONS
37	Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2523-2528.	2.0	57
38	Neurohormonal Blockade in Heart Failure. <i>Cardiac Failure Review</i> , 2017, 03, 19.	3.0	53
39	Redefining β -blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. <i>Lancet</i> , 2021, 398, 1427-1435.	13.7	52
40	Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. <i>The Cochrane Library</i> , 2010, , CD007613.	2.8	50
41	Five-minute heart rate variability can predict obstructive angiographic coronary disease. <i>Heart</i> , 2012, 98, 395-401.	2.9	50
42	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , 2019, 9, e022478.	1.9	50
43	Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review. <i>Europace</i> , 2017, 19, 1427-1438.	1.7	48
44	Totally thoracoscopic ablation for atrial fibrillation: a systematic safety analysis. <i>Europace</i> , 2018, 20, 1790-1797.	1.7	45
45	Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties. <i>PLoS ONE</i> , 2016, 11, e0165790.	2.5	44
46	Thoracoscopic Left Atrial Appendage Clipping. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 893-901.	3.2	42
47	Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. <i>BMC Medicine</i> , 2020, 18, 103.	5.5	40
48	Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial. <i>Europace</i> , 2019, 21, 746-753.	1.7	39
49	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2893-2904.	2.8	39
50	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.	1.7	38
51	ESC Core Curriculum for the Cardiologist. <i>European Heart Journal</i> , 2020, 41, 3605-3692.	2.2	38
52	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021, 23, 329-344.	1.7	38
53	Comorbidities in Heart Failure: Are There Gender Differences?. <i>Current Heart Failure Reports</i> , 2016, 13, 1-12.	3.3	37
54	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017, 7, e015099.	1.9	37

#	ARTICLE	IF	CITATIONS
55	In memoriam Henry Krum, 1958-2015. <i>Cardiology</i> , 2016, 134, 107-108.	1.4	34
56	Machine learning for subtype definition and risk prediction in heart failure, acute coronary syndromes and atrial fibrillation: systematic review of validity and clinical utility. <i>BMC Medicine</i> , 2021, 19, 85.	5.5	33
57	Incidence and clinical implications of intraoperative bilateral internal thoracic artery graft conversion: Insights from the Arterial Revascularization Trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2346-2355.e6.	0.8	28
58	Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. <i>Europace</i> , 2019, 21, 1776-1784.	1.7	22
59	Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design. <i>Systematic Reviews</i> , 2013, 2, 7.	5.3	21
60	Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1984-1986.	2.8	18
61	Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. <i>Evidence-Based Medicine</i> , 2014, 19, 222-223.	0.6	17
62	Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003599.	8.4	16
63	Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. <i>Heart</i> , 2019, 105, 1825-1831.	2.9	15
64	Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis. <i>Heart</i> , 2022, 108, 1600-1607.	2.9	15
65	B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease. <i>BMC Medicine</i> , 2019, 17, 72.	5.5	14
66	Digital learning and the future cardiologist. <i>European Heart Journal</i> , 2019, 40, 499-501.	2.2	14
67	Quality and Completeness of Myocardial Infarction Recording in Clinical Practice Research Datalink Aarum. <i>Clinical Epidemiology</i> , 2021, Volume 13, 745-753.	3.0	14
68	A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential. <i>European Journal of Heart Failure</i> , 2022, 24, 466-480.	7.1	14
69	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	2.2	14
70	Magnesium for Atrial Fibrillation, Myth or Magic?. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	4.8	12
71	Contemporary predictors of coronary artery disease in patients referred for angiography. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 280-288.	2.8	11
72	Radial artery pulse wave analysis for non-invasive assessment of coronary artery disease. <i>International Journal of Cardiology</i> , 2013, 167, 917-924.	1.7	11

#	ARTICLE	IF	CITATIONS
73	Increased Stroke Risk in Atrial Fibrillation Patients With Heart Failure. <i>Stroke</i> , 2015, 46, 608-609.	2.0	11
74	The future of continuing medical education: the roles of medical professional societies and the health care industry. <i>European Heart Journal</i> , 2019, 40, 1720-1727.	2.2	11
75	Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial). <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	10
76	ESC Apps for Atrial Fibrillation. <i>European Heart Journal</i> , 2017, 38, 2643-2645.	2.2	9
77	Is it time to treat post-operative atrial fibrillation just like regular atrial fibrillation?. <i>European Heart Journal</i> , 2019, 41, 652-654a.	2.2	9
78	Importance and Assessment of Quality of Life in Symptomatic Permanent Atrial Fibrillation: Patient Focus Groups from the RATE-AF Trial. <i>Cardiology</i> , 2020, 145, 666-675.	1.4	9
79	STEEER-AF: a cluster-randomized education trial from the ESC. <i>European Heart Journal</i> , 2020, 41, 1952-1954.	2.2	9
80	Identification and Mapping Real-World Data Sources for Heart Failure, Acute Coronary Syndrome, and Atrial Fibrillation. <i>Cardiology</i> , 2022, 147, 98-106.	1.4	9
81	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. <i>European Heart Journal</i> , 2019, 40, 1728-1738.	2.2	8
82	Transforming clinical research by involving and empowering patientsâ€” the RATE-AF randomized trial. <i>European Heart Journal</i> , 2021, 42, 2411-2414.	2.2	8
83	Effects of blood pressure-lowering drugs in heart failure. <i>Journal of Hypertension</i> , 2019, 37, 1757-1767.	0.5	7
84	Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021, 107, 902-908.	2.9	7
85	A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice. <i>Trials</i> , 2019, 20, 314.	1.6	6
86	All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. <i>American Journal of Therapeutics</i> , 2019, 26, e671-e678.	0.9	6
87	Longitudinal Assessment of Cardiac Involvement in Fabry Disease Using Cardiovascular Magnetic Resonance Imaging. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1850-1852.	5.3	5
88	Cardiac Imaging to Assess Left Ventricular Systolic Function in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 139, 40-49.	1.6	5
89	β blockers in patients with heart failure and atrial fibrillation â€” Authors' reply. <i>Lancet</i> , The, 2015, 385, 1618-1619.	13.7	4
90	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 591-599.	2.0	4

#	ARTICLE	IF	CITATIONS
91	Ambulatory blood pressure in atrial fibrillation: an irregular conundrum of rate and rhythm. Hypertension Research, 2013, 36, 854-855.	2.7	2
92	What's new in the 2016 ESC Guidelines on atrial fibrillation?. European Heart Journal, 2016, 37, 2851-2852.	2.2	2
93	Prognostic models for predicting incident or recurrent atrial fibrillation: protocol for a systematic review. Systematic Reviews, 2019, 8, 221.	5.3	2
94	Co-morbidity (HF _r EF and HF _p EF): atrial fibrillation. , 2018, , 1797-1801.		2
95	Qualifying the Use of Common Cardiovascular Drugs in Cardiology. Circulation Journal, 2015, 79, 517-518.	1.6	1
96	Digoxin – Friend or Foe? A Comprehensive Review of Digoxin use and Mortality. Heart, 2015, 101, A14.2-A15.	2.9	1
97	Response to the Letter from Dr. Wei Hui, Regarding the Recent Publication of “A Practical Guide to Assess the Reproducibility of Echocardiographic Measurements” Journal of the American Society of Echocardiography, 2020, 33, 1293.	2.8	1
98	Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation – Reply. JAMA - Journal of the American Medical Association, 2021, 325, 1681.	7.4	1
99	Improved Risk Prediction Using Non-Invasive Methods – The Alternative Risk Markers in Coronary Artery Disease (ARM-CAD) Study. Heart Lung and Circulation, 2008, 17, S72.	0.4	0
100	Letter: Conflicting and unresolved issue of the prognostic value of atrial fibrillation for chronic heart failure patients – Response. International Journal of Cardiology, 2016, 214, 516-517.	1.7	0
101	Authors' reply to Cunningham and Messerli and colleagues. BMJ, The, 2016, 353, i3141.	6.0	0
102	Observational Versus Randomized. JACC: Heart Failure, 2017, 5, 395-396.	4.1	0
103	Reply. Journal of the American College of Cardiology, 2018, 71, 105.	2.8	0
104	Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm?. European Journal of Heart Failure, 2019, 21, 480-481.	7.1	0
105	Education as a vehicle towards quality improvement in the European Society of Cardiology. Cardiovascular Research, 2019, 115, e80-e81.	3.8	0
106	A simple method to improve the reliability of echocardiography in patients with atrial fibrillation. , 2019, , .		0
107	Thienopyridines in Stable Coronary Disease. , 2010, , 131-141.		0